Risk of acute kidney injury and cost-effectiveness analysis comparing vancomycin and linezolid for the treatment of pediatric patients infected with Gram-positive bacteria

Oliveira, Laiane de Jesus; Ricieri, Marinei Campos; Fachi, Mariana Milan; Okumura, Lucas Miyake; Motta, Fábio Araújo.
J. bras. econ. saúde (Impr.) ; 14(Suplemento 2)20220800.
Artículo en Inglés | ECOS, LILACS | ID: biblio-1412751

Documentos relacionados

  1. Using Culture Sensitivity Reports to Optimize Antimicrobial Therapy: Findings and Implications of Antimicrobial Stewardship Activity in a Hospital in Pakistan.
  2. Cost-effectiveness of linezolid to ventilator-associated pneumonia in Colombia.
  3. Synthesis of Linezolid Metabolites PNU-142300 and PNU-142586 toward the Exploration of Metabolite-Related Events.
  4. Molecular detection of chloramphenicol-florfenicol resistance (cfr) genes among linezolid resistant MRSA isolates in Sokoto State, Nigeria
  5. Toxic neuropathies.
  6. Antimicrobial Synergistic Effects of Linezolid and Vancomycin with a Small Synthesized 2-Mercaptobenzothiazole Derivative: A Challenge for MRSA Solving.
  7. The effects of drug-drug interaction on linezolid pharmacokinetics: A systematic review.
  8. Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics.
  9. External Evaluation of Population Pharmacokinetics and Pharmacodynamics in Linezolid-Induced Thrombocytopenia: The Transferability of Published Models to Different Hospitalized Patients.
  10. A real-world cost-effectiveness study of vancomycin versus linezolid for the treatment of late-onset neonatal sepsis in the NICU in China.